A randomized phase II study of Cisplatin plus S-1 versus Cisplatin plus Pemetrexed, with thoracic radiotherapy for locally advanced non-squamous non-small cell lung cancer

INTERVENTION: Combination chemotherapy of S‐1 plus cisplatin and concurrent thoracic radiotherapy Combination chemotherapy of pemetrexed plus cisplatin and concurrent thoracic radiotherapy CONDITION: Non‐squmous non‐small cell lung cancer PRIMARY OUTCOME: 2‐year progression‐free survival rate SECONDARY OUTCOME: Rate of treatment completion, rate of adverse events, response rate, overall survival INCLUSION CRITERIA: (1) Pathologically proven non‐squamous non‐small cell lung cancer (2) Clinical stage IIIA or IIIB based on the UICC TNM classification 7th edition (3) Unresectable (4) Having indication of defenitive thoracic radiotherapy (5) No prior chemotherapy or radiotherapy (6) ECOG PS of 0 or 1 (7) PaO2 >= 70 Torr or SpO2 >= 93% (8) Adequate organ function (9) Expected the rest of life over 12 weeks (10) Age of 20 to 70 years (11) Written informed consent by patients